Research Faculty 게시판목록

Research Faculty & Scientists

Home
About Us
Research Faculty & Scientists

Weon-Kyoo You

{"firstName":"Weon-Kyoo","lastName":"You","position":"Research Professor","department":"Bio-Centennial Convergence Institute (Y-DDC)","homepages":["https://bcci.yonsei.ac.kr/bcci/center/y-ddc.do"],"homepage":"https://bcci.yonsei.ac.kr/bcci/center/y-ddc.do","orcid":"","googleScholar":"https://scholar.google.com/citations?user=P6-2vJEAAAAJ&hl=en","emails":["oneq@yonsei.ac.kr"],"email":"oneq@yonsei.ac.kr","phoneOffice":"02-2123-4341","phoneNumbers":[],"phoneLab":"","thumbAlt":"","listDescription":"","listThumbAlt":"","visibility":"public","researchKeywords":["Antibody-based therapeutics","Bispecific antibody","Blood-brain barrier (BBB) shuttle","Cancer & vascular biology"],"researchInterest":["Development of novel therapeutics with innovative drug modalities—including bispecific antibodies, antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and dual tyrosine kinase inhibitors and so on—from discovery to clinical stages across oncology, neuroscience, and cardiovascular biology.","Leading translational research in oncology, neuroscience, and cardiovascular biology to confirm proof of concept (PoC) and molecular mechanism of action (MoA), accelerating the transition of drug candidates into clinical trials."],"education":[{"period":"1999-2004","content":"Ph.D. Yonsei University"},{"period":"1993-1995","content":"M.S. Yonsei University"},{"period":"1987-1993","content":"B.S. Yonsei University"}],"career":[{"period":"2026-present","content":"Research Professor, Bio-Centennial Convergence Institute (Y-DDC), Yonsei University"},{"period":"2016-2025","content":"Executive Vice President, ABL Bio, Inc."},{"period":"2012-2016","content":"Principal Scientist, Hanwha Chemical, Biologics Business, R&D center"},{"period":"2009-2012","content":"Researcher, Sanford-Burnham Medical Research Institute"},{"period":"2004-2009","content":"Post-doc Fellow, University of California, San Francisco (UCSF)"},{"period":"2002-2006","content":"Research Head, Biobud Co. Ltd. (Currently NCBIT)"},{"period":"1999-2002","content":"Senior Researcher, Ilgin Materials (Pharmacy business department) (Currently ETEX Pharma)"},{"period":"1994-1999","content":"Senior Researcher, Mogam Biotechnology Research Institute"}],"patents":[{"year":"2025","content":"Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof"},{"year":"2024","content":"Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof"},{"year":"2024","content":"Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof"},{"year":"2024","content":"Anti-alpha-synuclein antibodies and uses thereof"},{"year":"2019","content":"Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof"},{"year":"2025","content":"BBB shuttle platform technology transfer to Eli Lilly (Nov. 2025, Upfront fee: 40 Million USD) & to GSK (May. 2025, Upfront fee: 38.5 Million Pound)"},{"year":"2022","content":"ABL301 (BBB-penetrating bispecific antibody for Parkinson’s disease treatment) program transfer to Sanofi (Jan. 2022, Upfront fee: 75 Million USD & Jan. 2023, 1st Millstone fee: 45 Million USD)"},{"year":"2020","content":"ABL202 (ROR1-binding antibody-drug conjugate, ADC for cancer treatment) program transfer to CStone Pharmaceuticals (Oct. 2020, Upfront fee: 4 Million USD)"},{"year":"2018","content":"ABL001 (bispecific antibody binding to VEGF & DLL4 for cancer treatment) program transfer to Compass Therapeutics (Nov. 2018, Upfront fee: 5 Million USD & Jun. 2022, 1st Millstone fee: 6 Million USD)"}],"awards":[{"period":"2024","content":"Industrial Research 52 (IR52) Jang Young-Shil Award"},{"period":"2019","content":"KFDA Award for enforcement of competitive power of Korean bio-therapeutics"},{"period":"2019","content":"Ministry of Health and Welfare Award for an excellent researcher to develop novel therapeutics"}]}
Se-Woong Oh

{"firstName":"Se-Woong","lastName":"Oh","position":"Research Professor","department":"Bio-Centennial Convergence Institute (Y-TCC)","homepages":[],"homepage":"","orcid":"","googleScholar":"https://scholar.google.co.kr/citations?hl=ko&user=hNDGm90AAAAJ","emails":["swoh33@yonsei.ac.kr"],"email":"swoh33@yonsei.ac.kr","phoneOffice":"02-2123-4342","phoneNumbers":[],"phoneLab":"","thumbAlt":"","listDescription":"","listThumbAlt":"","visibility":"public","researchKeywords":["Drug discovery and development","Translational Research","Oncology","Metabolic diseases","Immune & Inflammatory diseases"],"researchInterest":["Drawing upon extensive experience in pharmaceutical R&D leadership and global drug development, my core interest lies in the strategic translation of early-stage scientific discoveries into tangible healthcare innovations.","At Yonsei University, I am dedicated to bridging the critical gap between academia and industry by actively guiding basic science and clinical researchers through the complex pathways of commercialization.","By applying industry-standard translational strategies, my ultimate goal is to successfully transform these academic breakthroughs into market-ready new drugs and advanced medical devices that address unmet clinical needs."],"education":[{"period":"2002-2008","content":"Ph.D. Seoul National University"},{"period":"1993-1995","content":"M.S. Seoul National University"},{"period":"1989-1993","content":"B.S. Seoul National University"}],"career":[{"period":"2011-2025","content":"Senior principal scientist-CSO/EVP, Yuhan Corp."},{"period":"1999-2000","content":"Visiting scientist, School of Medicine, Univ. of Washington"},{"period":"1995-2011","content":"Research scientist-Team leader, JW Pharma Corp."}],"patents":[{"year":"2026","content":"Therapies with 3rd generation EGFR tyrosine kinase inhibitors"},{"year":"2025","content":"Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same"},{"year":"2021","content":"Pharmaceutical composition containing FGF21 mutant fusion protein"},{"year":"2019","content":"Collaboration and Licensing agreement with BI for dual GLP-1/FGF21 agonist for MASH"},{"year":"2019","content":"Licensing and collaboration agreement with Gilead for MASH"},{"year":"2018","content":"Lazertinib for lung cancer: Licensing and Co-development agreement with J&J"}],"awards":[{"period":"2019","content":"Order of Industrial Service Merit (Industrial Medal), President of the Republic of Korea"},{"period":"2013","content":"Minister’s Citation for Contribution to Health Industry, Ministry of Health and Welfare"}]}
Gahee Park

{"firstName":"Gahee","lastName":"Park","position":"Research Professor","department":"Bio-Centennial Convergence Institute (Omics Center)","homepages":["https://www.linkedin.com/in/gahee-park-64b23b56/?locale=en"],"homepage":"https://www.linkedin.com/in/gahee-park-64b23b56/?locale=en","orcid":"","googleScholar":"https://scholar.google.com/citations?user=1DDPkIkAAAAJ&hl=ko&oi=ao","emails":["gaheep217@yonsei.ac.kr"],"email":"gaheep217@yonsei.ac.kr","phoneOffice":"02-2123-4343","phoneNumbers":[],"phoneLab":"","thumbAlt":"","listDescription":"","listThumbAlt":"","visibility":"public","researchKeywords":["Liquid biopsy","Cancer genomics","Multi-Omics","Biomedical Imaging & AI","Translational Research"],"researchInterest":["Liquid biopsy and cancer genomics for early detection, disease progression, and treatment response.","Single-cell, spatial, and multi-omics approaches to understand cancer, aging, and tissue microenvironments.","Translational integration of multi-omics, biomedical imaging, and AI for biomarker discovery and precision medicine."],"education":[{"period":"2012-2018","content":"Ph.D. Seoul National University"},{"period":"2006-2010","content":"B.S. State University of New York at Buffalo"}],"career":[{"period":"2026-present","content":"Principal Researcher/Research Professor, Yonsei University"},{"period":"2025-present","content":"Visiting Researcher, University of Cambridge"},{"period":"2021-2025","content":"Senior Biomedical Research Associate, Lunit"},{"period":"2018-2021","content":"Postdoctoral Research Associate, University of Cambridge"},{"period":"2013-2018","content":"Researcher, Samsung Medical Center"}],"patents":[{"year":"2026","content":"Non-Invasive Disease Detection and Monitoring"},{"year":"2026","content":"Method and Device for Evaluating Quality of Pathological Slide Image"},{"year":"2025","content":"Method and Apparatus for Providing Examination-Related Guide on Basis of Tumor Content Predicted from Pathology Slide Images"},{"year":"2023","content":"Method and Apparatus for Tumor Purity Based on Pathological Slide Image"}],"awards":[{"period":"2020","content":"Professional Services Recognition Award, COVID-19 Testing Centre, University of Cambridge"},{"period":"2020","content":"CRUK Urological Malignancies Pump Priming Awards"},{"period":"2019","content":"Team Activity Winner, CRUK Cambridge Early Detection Programme Summer School"},{"period":"2019","content":"Poster Prize Winner, CRUK Early Detection Programme Annual Symposium"},{"period":"2018","content":"Rising Researcher, Young Korean Academy of Science and Technology (Y-KAST)"}]}
Jinhong Park

{"firstName":"Jinhong","lastName":"Park","position":"Research Professor","department":"Bio-Centennial Convergence Institute (Y-DDC)","homepages":["https://bcci.yonsei.ac.kr/bcci/center/y-ddc.do"],"homepage":"https://bcci.yonsei.ac.kr/bcci/center/y-ddc.do","orcid":"","googleScholar":"https://scholar.google.com/citations?user=gGUBSdUAAAAJ&hl=ko","emails":["jhpark2@yonsei.ac.kr"],"email":"jhpark2@yonsei.ac.kr","phoneOffice":"02-2123-4344","phoneNumbers":[],"phoneLab":"","thumbAlt":"","listDescription":"","listThumbAlt":"","visibility":"public","researchKeywords":["Drug Discovery","High-Throughput Screening","GPCRs and Ion channels","Small-molecule modulators"],"researchInterest":["High-Throughput screening (HTS)-Based Drug Discovery","Discovery of small-molecule modulators targeting GPCRs, ion channels, and other therapeutic targets through cell-based functional assays and pharmacological screening","Development of novel therapeutics for inflammatory diseases, hypertension, diabetes, dry eye disease, and metabolic acidosis","Translational Ion Channel and Receptor Biology","Functional studies of GPCRs and ion channels to elucidate disease mechanisms and identify novel therapeutic targets for drug discovery"],"education":[{"period":"2012-2016","content":"Ph.D. Yonsei University"},{"period":"2009-2011","content":"M.S. Korea University"},{"period":"2002-2009","content":"B.S. Korea University"}],"career":[{"period":"2026-present","content":"Research Professor, Bio-Centennial Convergence Institute, Yonsei University"},{"period":"2023-2026","content":"Professor (Project Faculty), Graduate Program of Industrial Pharmaceutical Sciences, Yonsei University"},{"period":"2023-2023","content":"Team Leader, Drug Discovery Team I, RudaCure Co., Ltd."},{"period":"2021-2023","content":"Postdoctoral Research Fellow, College of Pharmacy, Yonsei University"},{"period":"2018-2021","content":"Research Professor, Yonsei Institute of Pharmaceutical Sciences, Yonsei University"},{"period":"2016-2018","content":"Postdoctoral Research Fellow, College of Pharmacy, Yonsei University"}],"patents":[{"year":"2025","content":"Pharmaceutical Composition for Suppressing Gastric Acid Secretion Comprising SCL26A9 Inhibitor"},{"year":"2024","content":"Pharmaceutical composition for treating constipation comprising SCL26A3 and SLC26A6 dual inhibitor"},{"year":"2017","content":"Pharmacy composition for preventing or treating anti-cancer and expression depressant of ANO1"},{"year":"2016","content":"Pharmaceutical Compositions for the Treatment or Prevention of Cancers Comprising Idebenone"}],"awards":[]}